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It is generaly clainied that the dose of rHu Epo required is smaller when administrated by 
subcutaneous route (SC) than the inlravenous one (I.V.). However, a récent éditorial criticizes 
this statenient and stresses tlie point most comparative studies have not been performed in steady 
State conditions. 
The rHu Epo required to obtain a 30% hematocrit level was studied in 25 chronic hemodialvsed 
patients treated sucessfully for at least one year by EpO-SC- and shifted to the I.V. road. The 
mean weekh' dose required was estimated on t\vo times three months periods. The data were 
compared to 22 patients who remained treated by Epo I.V. during the whole observation period to 
detect seasonal or incidental variation of Epo needs. 
The table suinmarizes the main data. Although the mean Epo dose show a 22% increase, this 
différence does not reach significance level due to a very high variability between the patients. 
Further analysis howe\'er show a ver)' significant increase in the dose required in the patients 
receiving low dose of Epo (67±26 U/kg/w in the SÇ and 130±59 in the I.V. road) wheras in 
patients receiving high dose no change was obser\-ed (182±97 and 162±128). 
The increase in the dose required was alread)' obser\ed during the first months of use of the I.V. 
road. During the same period. the Epo dose required was not change in the control group. 
S.C. I.V. p* 
Dose (U/kg/week) 122,04 90,13 145,9 ± 97,8 NS 
Hbgr% 9,84 ±0,87 10,12 ±0 ,57 NS 
Hct% 30,06 ± 2,5 32 ±2 ,04 0,003 
NBR RBC 3,39 ±0 ,42 3,41 ±0 ,46 NS 
Reticuloc>1es 2,31 ± 0,79 2,68 ± 0,96 NS 
Ferritin 71,8 ± 35,11 73,42 ± 38,22 NS 
*t student for paired data NS: >0,05 
Conclusion: As a whole the administration of rHu Epo by I.V. lead to an 20% increase of the dose 
required, but this change is only significant in patients receiving rather small dose, lower than 100 
U/kg/week. 
